Bio-Thera Receives Approval for Clinical Trials of BAT5906, an Innovative Recombinant Anti-VEGF Humanized Monoclonal Antibody

1 week ago / Read about 0 minute

Author：小编

Bio-Thera has announced that its proprietary recombinant anti-VEGF humanized monoclonal antibody injection, BAT5906, has secured approval from the National Medical Products Administration (NMPA) for additional clinical trials. These trials will focus on the treatment of macular edema caused by central retinal vein occlusion (CRVO-ME) and choroidal neovascularization in pathological myopia (pmCNV). BAT5906, an innovative drug developed by Bio-Thera, has already completed Phase I, II, and III clinical studies for wet age-related macular degeneration (w-AMD) and Phase II clinical studies for diabetic macular edema (DME). Currently, the drug is in the preparation stage for Phase II/III clinical trials targeting CRVO-ME and pmCNV indications.

Previous page：Musk Announces Plans for Mid-August Starship Launc...

Next page：Wasion Information Secures RMB 110 Million in Proc...

Return to List

Hot Reading

22 hour ago

Why it’s a mistake to ask chatbots about their mistakes

22 hour ago

ChatGPT’s model picker is back, and it’s complicated

23 hour ago

Perplexity offers more than twice its total valuation to buy Chrome from Google

2 day ago

Grok Is So Deeply Antisemitic That Showing It a Picture of Some Random Clouds in the Sky Prompts an Outrageously Offensive Answer